Candidate Nomination
We provide solutions to identify and develop your best lead candidate. (non-GLP screening, Toxicity focused assessment)
IND enabling Nonclinical assessment
We integrate lead optimization, safety pharmacology, toxicology, pathology, bioanalytical, drug metabolism and pharmacokinetics to assure successful IND submission and lead towards FIH studies
First-in-human(FIH) studies
We will rely on the early phase non-clinical (DRF and GLP) studies to move the compound into FIH and sharpen the focus on scientific integrity(protocol study design, population, endpoint) and human subject safety
Proof of Concept studies (POC)
We provide expertise to design small-scale clinical studies to detect a signal that the drug is active on a pathophysiologically relevant mechanism, as well as preliminary evidence of efficacy in a clinically relevant endpoint.